sample	drug	gatkscore	depth	readsratio	gene	diplotype	cHGVS	pHGVS	zyg	guide	advice	effect	suggest	ref_guide	drugid	rsID	location
Test	别嘌醇	.	.	.	ABCG2	rs2231142 reference (G)/rs2231142 reference (G)	.	.	Hom		The guideline does not provide a description of the impact of the ABCG2 rs2231142 GG genotype (c.421CC; p.141QQ) on allopurinol.		The guideline does not provide a recommendation for allopurinol in patients with the the ABCG2 rs2231142 GG genotype (c.421CC; p.141QQ)	DPWG Guideline Annotation	PA448320	.	.
Test	瑞舒伐他汀	.	.	.	ABCG2	rs2231142 reference (G)/rs2231142 reference (G)	.	.	Hom		ABCG2: Typical myopathy risk and rosuvastatin exposure;SLCO1B1: Increased rosuvastatin exposure as compared to normal function and decreased function; Typical myopathy risk with doses ≤20 mg.		"Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose &gt; 20mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	.	.
Test	地氟烷	.	.	.	CACNA1S	Reference/Reference	.	.	Hom		These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).		Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	CPIC Guideline Annotation	PA164749136	.	.
Test	恩氟烷	.	.	.	CACNA1S	Reference/Reference	.	.	Hom		These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).		Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	CPIC Guideline Annotation	PA449461	.	.
Test	氟烷	.	.	.	CACNA1S	Reference/Reference	.	.	Hom		These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).		Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	CPIC Guideline Annotation	PA449845	.	.
Test	异氟烷	.	.	.	CACNA1S	Reference/Reference	.	.	Hom		These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).		Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	CPIC Guideline Annotation	PA450106	.	.
Test	甲氧氟烷	.	.	.	CACNA1S	Reference/Reference	.	.	Hom		These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).		Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	CPIC Guideline Annotation	PA450434	.	.
Test	七氟烷	.	.	.	CACNA1S	Reference/Reference	.	.	Hom		These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).		Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	CPIC Guideline Annotation	PA451341	.	.
Test	琥珀胆碱	.	.	.	CACNA1S	Reference/Reference	.	.	Hom		These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).		Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	CPIC Guideline Annotation	PA451522	.	.
Test	舍曲林	.	.	.	CYP2B6	*1/*1	.	.	Hom		CYP2B6: Normal metabolism of sertraline to less active compounds.;CYP2C19: Normal metabolism		Initiate therapy with recommended starting dose.	CPIC Guideline Annotation	PA451333	.	.
Test	阿米替林	1478.06	0,46	1.0	CYP2C19	*1/*1	test	test	Hom		CYP2C19: Normal metabolism of tertiary amines;CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects	Normal Metabolizer	"Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain."	CPIC Guideline Annotation	PA448385	rs3758581	chr10:94842866:A>G
Test	西酞普兰	1478.06	0,46	1.0	CYP2C19	*1/*1	test	test	Hom		CYP2C19: Normal metabolism	Normal Metabolizer	Initiate therapy with recommended starting dose	CPIC Guideline Annotation	PA449015	rs3758581	chr10:94842866:A>G
Test	氯米帕明	1478.06	0,46	1.0	CYP2C19	*1/*1	test	test	Hom		CYP2C19: Normal metabolism of tertiary amines;CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects	Normal Metabolizer	"Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain."	CPIC Guideline Annotation	PA449048	rs3758581	chr10:94842866:A>G
Test	氯吡格雷	1478.06	0,46	1.0	CYP2C19	*1/*1	test	test	Hom		CYP2C19: Normal clopidogrel active metabolite formation; normal on-treatment platelet reactivity	Normal Metabolizer	"If considering clopidogrel, use at standard dose (75 mg/day)
<h4 id=""other-considerations"">Other Considerations</h4>
For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication."	CPIC Guideline Annotation	PA449053	rs3758581	chr10:94842866:A>G
Test	右兰索拉唑	1478.06	0,46	1.0	CYP2C19	*1/*1	test	test	Hom		CYP2C19: Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs	Normal Metabolizer	"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy."	CPIC Guideline Annotation	PA166110257	rs3758581	chr10:94842866:A>G
Test	多塞平	1478.06	0,46	1.0	CYP2C19	*1/*1	test	test	Hom		CYP2C19: Normal metabolism of tertiary amines;CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects	Normal Metabolizer	"Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain."	CPIC Guideline Annotation	PA449409	rs3758581	chr10:94842866:A>G
Test	艾司西酞普兰	1478.06	0,46	1.0	CYP2C19	*1/*1	test	test	Hom		CYP2C19: Normal metabolism	Normal Metabolizer	Initiate therapy with recommended starting dose	CPIC Guideline Annotation	PA10074	rs3758581	chr10:94842866:A>G
Test	丙米嗪	1478.06	0,46	1.0	CYP2C19	*1/*1	test	test	Hom		CYP2C19: Normal metabolism of tertiary amines;CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects	Normal Metabolizer	"Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain."	CPIC Guideline Annotation	PA449969	rs3758581	chr10:94842866:A>G
Test	兰索拉唑	1478.06	0,46	1.0	CYP2C19	*1/*1	test	test	Hom		CYP2C19: Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs	Normal Metabolizer	"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy."	CPIC Guideline Annotation	PA450180	rs3758581	chr10:94842866:A>G
Test	奥美拉唑	1478.06	0,46	1.0	CYP2C19	*1/*1	test	test	Hom		CYP2C19: Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs	Normal Metabolizer	"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy."	CPIC Guideline Annotation	PA450704	rs3758581	chr10:94842866:A>G
Test	泮托拉唑	1478.06	0,46	1.0	CYP2C19	*1/*1	test	test	Hom		CYP2C19: Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs	Normal Metabolizer	"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy."	CPIC Guideline Annotation	PA450774	rs3758581	chr10:94842866:A>G
Test	舍曲林	1478.06	0,46	1.0	CYP2C19	*1/*1	test	test	Hom		CYP2B6: Normal metabolism of sertraline to less active compounds.;CYP2C19: Normal metabolism	Normal Metabolizer	Initiate therapy with recommended starting dose.	CPIC Guideline Annotation	PA451333	rs3758581	chr10:94842866:A>G
Test	曲米帕明	1478.06	0,46	1.0	CYP2C19	*1/*1	test	test	Hom		CYP2C19: Normal metabolism of tertiary amines;CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects	Normal Metabolizer	"Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain."	CPIC Guideline Annotation	PA451791	rs3758581	chr10:94842866:A>G
Test	伏立康唑	1478.06	0,46	1.0	CYP2C19	*1/*1	test	test	Hom		CYP2C19: Normal voriconazole metabolism	Normal Metabolizer	"Initiate therapy with recommended standard of care dosing
<h4 id=""other-considerations"">Other Considerations</h4>
Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities."	CPIC Guideline Annotation	PA10233	rs3758581	chr10:94842866:A>G
Test	氟伐他汀	.	.	.	CYP2C9	*1/*1	.	.	Hom		CYP2C9: Normal exposure.;SLCO1B1: Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg.		"Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (&gt;40mg) or an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	.	.
Test	磷苯妥英	.	.	.	CYP2C9	*1/*1	.	.	Hom		CYP2C9: Normal phenytoin metabolism;HLA-B: Increased risk of phenytoin-induced SJS/TEN		"If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
<h4 id=""other-considerations"">Other Considerations</h4>
Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent."	CPIC Guideline Annotation	PA164746820	.	.
Test	苯妥英	.	.	.	CYP2C9	*1/*1	.	.	Hom		CYP2C9: Normal phenytoin metabolism;HLA-B: Increased risk of phenytoin-induced SJS/TEN		"If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
<h4 id=""other-considerations"">Other Considerations</h4>
Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent."	CPIC Guideline Annotation	PA450947	.	.
Test	华法林	.	.	.	CYP2C9	*1/*1	.	.	Hom				.	CPIC Guideline Annotation	PA451906	.	.
Test	阿米替林	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		CYP2C19: Normal metabolism of tertiary amines;CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects	Intermediate Metabolizer	"Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain."	CPIC Guideline Annotation	PA448385	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	阿莫沙平	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het			Intermediate Metabolizer	&quot;May alter systemic concentrations.&quot;	FDA PGx Association	PA448405	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	阿立哌唑	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		The genetic variation increases the plasma concentration of the sum of aripiprazole and the active metabolite dehydroaripiprazole to a limited degree. There is insufficient evidence that this increases the risk of side effects.	Intermediate Metabolizer	NO action is needed for this gene-drug interaction.	DPWG Guideline Annotation	PA10026	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	托莫西汀	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		CYP2D6: Possibly higher atomoxetine concentrations as compared to normal metabolizers but questionable clinical significance. Intermediate metabolizers with an activity score of 1 may be at an increased risk of discontinuation as compared to poor metabolizers.	Intermediate Metabolizer	"Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If &lt;200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.
<h4 id=""other-considerations"">Other Considerations</h4>
Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated."	CPIC Guideline Annotation	PA134688071	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	依匹哌唑	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		There are indications supporting an increase in the exposure to brexpiprazole, but no indications supporting an increase in side effects in patients with this gene variation.	Intermediate Metabolizer	NO action is required for this gene-drug interaction.	DPWG Guideline Annotation	PA166160053	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	氯米帕明	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		CYP2C19: Normal metabolism of tertiary amines;CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects	Intermediate Metabolizer	"Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain."	CPIC Guideline Annotation	PA449048	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	可待因	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		CYP2D6: Reduced morphine formation	Intermediate Metabolizer	Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.	CPIC Guideline Annotation	PA449088	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	去甲丙米嗪	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.	Intermediate Metabolizer	"Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain."	CPIC Guideline Annotation	PA449233	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	多塞平	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		CYP2C19: Normal metabolism of tertiary amines;CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects	Intermediate Metabolizer	"Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain."	CPIC Guideline Annotation	PA449409	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	依利格鲁司他	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		This gene variation reduces the conversion of eliglustat to inactive metabolites. However, in the absence of CYP2D6 and CYP3A inhibitors, this does not result in a clinically significant increased risk of side effects.	Intermediate Metabolizer	"Co-medication with BOTH a MODERATE to STRONG CYP2D6 INHIBITOR AND a MODERATE to STRONG CYP3A INHIBITOR:
<ul>
<li>Eliglustat is contra-indicated. Choose an alternative if possible.</li>
</ul>
<em>Strong CYP2D6 inhibitor: for example paroxetine, fluoxetine, quinidine, bupropione. Moderate CYP2D6 inhibitor: for example duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone. Strong CYP3A inhibitor: for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir. Moderate CYP3A inhibitor: for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine.</em>
Co-medication with a STRONG CYP2D6 INHIBITOR (e.g. paroxetine, fluoxetine, quinidine, bupropione):
<ul>
<li>Use a dose of 84mg eliglustat 1x daily.</li>
</ul>
Co-medication with a MODERATE CYP2D6 INHIBITOR (for example duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone):
<ul>
<li>Consider a dose of 84mg eliglustat 1x daily. Be alert to side effects.</li>
</ul>
Co-medication with a STRONG CYP3A INHIBITOR (for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir):
<ul>
<li>Choose an alternative if possible.</li>
<li>If an alternative is not an option: consider a dose of 84 mg eliglustat 1x daily and be alert to side effects.</li>
</ul>
Co-medication with a MODERATE CYP3A INHIBITOR (for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine):
<ul>
<li>Choose an alternative.</li>
<li>If an alternative is not an option: consider a dose of 84mg eliglustat 1x daily and be alert to side effects.</li>
</ul>
Co-medication with a STRONG CYP3A INDUCER (for example rifampicin, carbamazepine, phenobarbital, phenytoin, rifabutine, hypericum): Eliglustat is not recommended. The plasma concentration may decrease so sharply that a therapeutic effect cannot be achieved.
<ul>
<li>Choose an alternative if possible.</li>
</ul>
NO co-medication with a moderate or strong CYP2D6 or CYP3A inhibitor or strong CYP3A inducer:
<ul>
<li>Use the standard dose of 84mg 2x daily.</li>
</ul>"	DPWG Guideline Annotation	PA166123486	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	氟伏沙明	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		CYP2D6: Reduced metabolism of fluvoxamine to less active compounds when compared to CYP2D6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.	Intermediate Metabolizer	Initiate therapy with recommended starting dose.	CPIC Guideline Annotation	PA449690	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	氢可酮	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		CYP2D6: Minimal evidence for pharmacokinetic or clinical effect.	Intermediate Metabolizer	Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid.	CPIC Guideline Annotation	PA449900	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	丙米嗪	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		CYP2C19: Normal metabolism of tertiary amines;CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects	Intermediate Metabolizer	"Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain."	CPIC Guideline Annotation	PA449969	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	美克洛嗪	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		"""The genetic polymorphism of CYP2D6 that results in poor-, intermediate-, extensive-, and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure."""	Intermediate Metabolizer	&quot;... when ANTIVERT® [meclizine] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.&quot; See label for more information.	FDA Label Annotation	PA450338	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	美托洛尔	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		Decreased metabolism of metoprolol leading to increased drug concentrations; however, this does not appear to translate into clinically significant changes in heart rate, blood pressure, or clinical outcomes	Intermediate Metabolizer	Initiate standard dosing	CPIC Guideline Annotation	PA450480	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	去甲替林	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		CYP2D6: Reduced metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.	Intermediate Metabolizer	"Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of tricyclic antidepressants for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain."	CPIC Guideline Annotation	PA450657	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	昂丹司琼	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		CYP2D6: Very limited data available for CYP2D6 intermediate metabolizers	Intermediate Metabolizer	"Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.
<h4 id=""other-considerations"">Other Considerations</h4>
Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy."	CPIC Guideline Annotation	PA450705	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	帕罗西汀	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		"CYP2D6: Reduced metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers when starting treatment or at lower doses. Higher plasma concentrations may increase the probability of side
effects. Paroxetine-associated phenoconversion of intermediate metabolizers to poor metabolizers due to CYP2D6 autoinhibition may occur and is dose-dependent and greater at steady state concentrations."	Intermediate Metabolizer	"Consider a lower starting dose and slower titration schedule as compared to normal metabolizers.
<h4 id=""other-considerations"">Other Considerations</h4>
Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose or selecting an alternative therapy."	CPIC Guideline Annotation	PA450801	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	匹莫齐特	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		The risk of QT-prolongation – and thereby also the risk of torsade de points – is theoretically increased, because the genetic variation results in an increase in the plasma concentration of pimozide. The elevated plasma concentration and associated theoretical increased risk of QT elongation can be negated by following the dose recommendations provided below.	Intermediate Metabolizer	"Use no more than the following doses (80% of the normal maximum dose):
<ul>
<li>12 years and older: 16 mg/day</li>
<li>younger than 12 years: 0.08 mg/kg per day to a maximum of 3 mg/day</li>
</ul>"	DPWG Guideline Annotation	PA450965	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	普罗帕酮	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		Genetic variation increases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This may increase the risk of side effects.	Intermediate Metabolizer	"It is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.
<ul>
<li>Either guide the dose by therapeutic drug monitoring, perform an ECG and be alert to side effects.</li>
<li>Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone.</li>
</ul>"	DPWG Guideline Annotation	PA451131	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	利培酮	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		There is little evidence to support an increase in side effects caused by the gene variation. The gene variation may lead to a decrease in the required maintenance dose. However, as the effect on the dose is smaller than that of the normal biological variation, action is not useful.	Intermediate Metabolizer	NO action is needed for this gene-drug interaction.	DPWG Guideline Annotation	PA451257	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	他莫昔芬	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		CYP2D6: Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers.	Intermediate Metabolizer	Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.	CPIC Guideline Annotation	PA451581	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	丁苯那嗪	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het			Intermediate Metabolizer	"&quot;Genotyped patients who are identified as extensive (EMs) or intermediate metabolizers (IMs) of
CYP2D6, who need doses of XENAZINE [tetrabenazine] above 50 mg per day, should be titrated up slowly at
weekly intervals by 12.5 mg daily, to allow the identification of a tolerated dose that reduces
chorea. Doses above 50 mg per day should be given in a three times a day regimen. The
maximum recommended daily dose is 100 mg and the maximum recommended single dose is
37.5 mg. If adverse reactions such as akathisia, parkinsonism, depression, insomnia, anxiety or
sedation occur, titration should be stopped and the dose should be reduced. If the adverse
reaction does not resolve, consideration should be given to withdrawing XENAZINE [tetrabenazine] treatment
or initiating other specific treatment.&quot; See label for more information"	FDA Label Annotation	PA140222719	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	硫利达嗪	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het			Intermediate Metabolizer	&quot;...thioridazine is contraindicated...in patients, comprising about 7% of the normal population, who are known to have a genetic defect leading to reduced levels of activity of P450 2D6.&quot; See label for more information.	FDA Label Annotation	PA451666	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	曲马多	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		CYP2D6: Reduced O-desmethyltramadol (active metabolite) formation	Intermediate Metabolizer	Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.	CPIC Guideline Annotation	PA451735	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	曲米帕明	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		CYP2C19: Normal metabolism of tertiary amines;CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects	Intermediate Metabolizer	"Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain."	CPIC Guideline Annotation	PA451791	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	托烷司琼	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		CYP2D6: Very limited data available for CYP2D6 intermediate metabolizers	Intermediate Metabolizer	"Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.
<h4 id=""other-considerations"">Other Considerations</h4>
Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy."	CPIC Guideline Annotation	PA161925594	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	文拉法辛	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		CYP2D6: Decreased metabolism of venlafaxine to active metabolite O-desmethylvenlafaxine (desvenlafaxine) and decreased O-desmethylvenlafaxine:venlafaxine ratio as compared to normal metabolizers. There is insufficient evidence supporting the clinical impact of the decreased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 intermediate metabolizers.	Intermediate Metabolizer	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	CPIC Guideline Annotation	PA451866	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	伏硫西汀	314.64,577.64,513.64	12,18;22,17;15,11	0.6;0.44;0.42	CYP2D6	*1/*3	test	test	Het		CYP2D6: Reduced metabolism of vortioxetine to less active compounds when compared to CYP2D6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.	Intermediate Metabolizer	Initiate therapy with recommended starting dose.	CPIC Guideline Annotation	PA166122595	rs1058164,rs1135840,rs1065852	chr22:42130692:G>A,chr22:42129130:C>G,chr22:42126611:C>G
Test	他克莫司	1807.06	0,52	1.0	CYP3A5	*3/*3	test	test	Hom		"CYP3A5: Higher (""normal"") dose-adjusted trough concentrations of tacrolimus and increased chance of achieving target tacrolimus concentrations."	Poor Metabolizer	"Initiate therapy with standard recommended dose. Use therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
This recommendation includes the use of tacrolimus in kidney, heart, lung and hematopoietic stem cell transplant patients, and liver transplant patients where the donor and recipient genotypes are identical. Typically with other CYP enzymes, a normal metabolizer would be classified as having normal metabolism, and therefore, the drug dose would not change based on the patient’s genotype. However, in the case of CYP3A5 and tacrolimus, a CYP3A5 expresser (i.e., CYP3A5 normal metabolizer or intermediate metabolizer) would require a higher recommended starting dose and the CYP3A5 non-expresser (i.e., poor metabolizer) would require the standard recommended starting dose."	CPIC Guideline Annotation	PA451578	rs776746	chr7:99672916:T>C
Test	华法林	56.64	39,7	0.15	CYP4F2	*1/*17	test	test	Het				.	CPIC Guideline Annotation	PA451906	rs4020346	chr19:15878920:T>C
Test	卡培他滨	560.64	21,18	0.46	DPYD	Reference/c.1627A>G (*5)	test	test	Het		"DPYD: Normal DPD activity and ""normal"" risk for fluoropyrimidine toxicity"	Normal Metabolizer	Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.	CPIC Guideline Annotation	PA448771	rs1801159	chr1:97515839:T>C
Test	氟尿嘧啶	560.64	21,18	0.46	DPYD	Reference/c.1627A>G (*5)	test	test	Het		"DPYD: Normal DPD activity and ""normal"" risk for fluoropyrimidine toxicity"	Normal Metabolizer	Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.	CPIC Guideline Annotation	PA128406956	rs1801159	chr1:97515839:T>C
Test	卡马西平	.	.	.	HLA-A	*31:01/*31:01	.	.	Hom		HLA-A: Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE;HLA-B: Greater risk of carbamazepine-induced SJS/TEN	*31:01 positive	"If patient is carbamazepine-naïve, do not use carbamazepine.
<h4 id=""other-considerations"">Other Considerations</h4>
Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered."	CPIC Guideline Annotation	PA448785	.	.
Test	阿巴卡韦	.	.	.	HLA-B	*15:02/*57:01	.	.	Het		HLA-B: Significantly increased risk of abacavir hypersensitivity	*15:02 positive	Abacavir is not recommended	CPIC Guideline Annotation	PA448004	.	.
Test	别嘌醇	.	.	.	HLA-B	*15:02/*57:01	.	.	Het		HLA-B: Low or reduced risk of allopurinol-induced SCAR	*15:02 positive	Use allopurinol per standard dosing guidelines	CPIC Guideline Annotation	PA448320	.	.
Test	卡马西平	.	.	.	HLA-B	*15:02/*57:01	.	.	Het		HLA-A: Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE;HLA-B: Greater risk of carbamazepine-induced SJS/TEN	*15:02 positive	"If patient is carbamazepine-naïve, do not use carbamazepine.
<h4 id=""other-considerations"">Other Considerations</h4>
Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered."	CPIC Guideline Annotation	PA448785	.	.
Test	磷苯妥英	.	.	.	HLA-B	*15:02/*57:01	.	.	Het		CYP2C9: Normal phenytoin metabolism;HLA-B: Increased risk of phenytoin-induced SJS/TEN	*15:02 positive	"If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
<h4 id=""other-considerations"">Other Considerations</h4>
Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent."	CPIC Guideline Annotation	PA164746820	.	.
Test	奥卡西平	.	.	.	HLA-B	*15:02/*57:01	.	.	Het		HLA-B: Greater risk of oxcarbazepine-induced SJS/TEN	*15:02 positive	"If patient is oxcarbazepine-naïve, do not use oxcarbazepine.
<h4 id=""other-considerations"">Other Considerations</h4>
Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital."	CPIC Guideline Annotation	PA450732	.	.
Test	帕唑帕尼	.	.	.	HLA-B	*15:02/*57:01	.	.	Het			*15:02 positive	&quot;May result in higher adverse reaction risk (liver enzyme elevations). Monitor liver function tests regardless of genotype.&quot;	FDA PGx Association	PA165291492	.	.
Test	苯妥英	.	.	.	HLA-B	*15:02/*57:01	.	.	Het		CYP2C9: Normal phenytoin metabolism;HLA-B: Increased risk of phenytoin-induced SJS/TEN	*15:02 positive	"If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
<h4 id=""other-considerations"">Other Considerations</h4>
Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent."	CPIC Guideline Annotation	PA450947	.	.
Test	地氟烷	839.64	18,25	0.58	RYR1	Reference/c.11266C>G	test	test	Het		These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).	Uncertain Susceptibility	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	CPIC Guideline Annotation	PA164749136	rs4802584	chr19:38534726:C>G
Test	恩氟烷	839.64	18,25	0.58	RYR1	Reference/c.11266C>G	test	test	Het		These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).	Uncertain Susceptibility	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	CPIC Guideline Annotation	PA449461	rs4802584	chr19:38534726:C>G
Test	氟烷	839.64	18,25	0.58	RYR1	Reference/c.11266C>G	test	test	Het		These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).	Uncertain Susceptibility	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	CPIC Guideline Annotation	PA449845	rs4802584	chr19:38534726:C>G
Test	异氟烷	839.64	18,25	0.58	RYR1	Reference/c.11266C>G	test	test	Het		These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).	Uncertain Susceptibility	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	CPIC Guideline Annotation	PA450106	rs4802584	chr19:38534726:C>G
Test	甲氧氟烷	839.64	18,25	0.58	RYR1	Reference/c.11266C>G	test	test	Het		These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).	Uncertain Susceptibility	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	CPIC Guideline Annotation	PA450434	rs4802584	chr19:38534726:C>G
Test	七氟烷	839.64	18,25	0.58	RYR1	Reference/c.11266C>G	test	test	Het		These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).	Uncertain Susceptibility	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	CPIC Guideline Annotation	PA451341	rs4802584	chr19:38534726:C>G
Test	琥珀胆碱	839.64	18,25	0.58	RYR1	Reference/c.11266C>G	test	test	Het		These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).	Uncertain Susceptibility	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	CPIC Guideline Annotation	PA451522	rs4802584	chr19:38534726:C>G
Test	阿托伐他汀	1536.06,1829.06	0,47;0,55	1.0	SLCO1B1	*15/*15	test	test	Hom		SLCO1B1: Increased atorvastatin exposure as compared to normal and decreased function which may translate to increased myopathy risk.	Poor Function	"Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If dose &gt;20mg is needed for desired efficacy, consider rosuvastatin or combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA448500	rs4149056,rs2306283	chr12:21176804:A>G,chr12:21178615:T>C
Test	艾拉戈利	1536.06,1829.06	0,47;0,55	1.0	SLCO1B1	*15/*15	test	test	Hom			Poor Function	&quot;Results in higher systemic concentrations.&quot;	FDA PGx Association	PA166182348	rs4149056,rs2306283	chr12:21176804:A>G,chr12:21178615:T>C
Test	氟伐他汀	1536.06,1829.06	0,47;0,55	1.0	SLCO1B1	*15/*15	test	test	Hom		CYP2C9: Normal exposure.;SLCO1B1: Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg.	Poor Function	"Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (&gt;40mg) or an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA449688	rs4149056,rs2306283	chr12:21176804:A>G,chr12:21178615:T>C
Test	洛伐他汀	1536.06,1829.06	0,47;0,55	1.0	SLCO1B1	*15/*15	test	test	Hom		SLCO1B1: Increased lovastatin acid exposure as compared to normal and decreased function which may translate to increased myopathy risk	Poor Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA450272	rs4149056,rs2306283	chr12:21176804:A>G,chr12:21178615:T>C
Test	匹伐他汀	1536.06,1829.06	0,47;0,55	1.0	SLCO1B1	*15/*15	test	test	Hom		SLCO1B1: Increased pitavastatin exposure as compared to normal and decreased function which may translate to increased myopathy risk.	Poor Function	"Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If dose &gt;1mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy)(PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA142650384	rs4149056,rs2306283	chr12:21176804:A>G,chr12:21178615:T>C
Test	普伐他汀	1536.06,1829.06	0,47;0,55	1.0	SLCO1B1	*15/*15	test	test	Hom		SLCO1B1: Increased pravastatin statin exposure as compared to normal and decreased function; Typical myopathy risk with doses ≤40 mg.	Poor Function	"Prescribe ≤40mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If patient is tolerating 40mg dose but higher potency is needed, a higher dose (&gt;40mg) or an alternative statin (see Figure 1 of of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pravastatin plus non-statin guideline directed medical therapy)(PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy especially with pravastatin doses &gt;40mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451089	rs4149056,rs2306283	chr12:21176804:A>G,chr12:21178615:T>C
Test	瑞舒伐他汀	1536.06,1829.06	0,47;0,55	1.0	SLCO1B1	*15/*15	test	test	Hom		ABCG2: Typical myopathy risk and rosuvastatin exposure;SLCO1B1: Increased rosuvastatin exposure as compared to normal function and decreased function; Typical myopathy risk with doses ≤20 mg.	Poor Function	"Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose &gt; 20mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA134308647	rs4149056,rs2306283	chr12:21176804:A>G,chr12:21178615:T>C
Test	辛伐他汀	1536.06,1829.06	0,47;0,55	1.0	SLCO1B1	*15/*15	test	test	Hom		SLCO1B1: Increased simvastatin acid exposure compared to normal and decreased function; highly increased myopathy risk	Poor Function	"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."	CPIC Guideline Annotation	PA451363	rs4149056,rs2306283	chr12:21176804:A>G,chr12:21178615:T>C
Test	华法林	1626.06	0,42	1.0	VKORC1	rs9923231 variant (T)/rs9923231 variant (T)	test	test	Hom				.	CPIC Guideline Annotation	PA451906	rs9923231	chr16:31096368:C>T
